替吉奥与卡培他滨在老年晚期胃癌患者治疗中的药物经济学分析

Analysis of pharmacoeconomics of gimeracil and oteracil porassium capsules versus capecitabine in treatment of elderly patients with advanced gastric cancer

目的评价替吉奥胶囊与卡培他滨片治疗老年晚期胃癌患者的成本-效果,为临床合理用药提供指导。方法选取老年晚期胃癌患者(年龄>65岁)76例(替吉奥组40例,卡培他滨组36例),比较口服用药6周期后的疗效、不良反应及治疗成本,并进行成本-效果分析。结果替吉奥组与卡培他滨组的治疗肿瘤控制率分别为53%、56%,两组间疗效无显著差异(P>0.05);成本/效果比(C/E)分别为411.91和517.24;卡培他滨组的口腔炎及手足综合征不良反应发生率较替吉奥组高(P<0.05),其他不良反应发生率无显著差异。结论替吉奥与卡培他滨用于治疗晚期胃癌的近期疗效相似,替吉奥治疗老年晚期胃癌患者在药物经济学上优于卡培他滨。

AIM To evaluate the cost effectiveness of gimeracil and oteracil porassium capsules and capecitabine in the treatment of the elderly patients with advanced gastric cancer, providing the guidance on clinical medication. METHODS A total of 76 elderly patients with advanced gastric cancer were treated by gimeracil and oteracil porassium capsules （n = 40） or capecitabine tablets （n = 36）. The doses of the two drugs were given according to the pharmaceutical directions by body surface area, and cycles were repeated every twenty-one days with oral drugs up to fourteen days. The efficacy, adverse drug reactions were evaluated, and the cost effectiveness were analyzed after treatment of six cycles. RESULTS The tumor control rate of gimeracil and oteracil porassium capsules and capecitabine was difference （P 〉 0.05）. The cost effectiveness of gimeracil and 53% and 56% respectively, with no significant oteracil porassium capsules and capecitabine was411.91 and 517.24. The incidence of adverse drug reactions was similar, except that the incidence of stomatitis and hand- foot syndrome in the gimeracil and oteracil potassium capsules group was lower than in the capecitabine group （P 〈 0.05）. CONCLUSION Considering pharmacoeconomics, gimeracil and oteracil porassium capsules would be the better choice for the elderly patients with advanced gastric cancer.